Sepsis Diagnostics by Microbiology Technology Market Research Report - Segmentation by Product (Assays & Reagents, Blood Culture Media, Instruments, Software); Method (Automated Diagnostics, Conventional Diagnostics); Pathogen Type (Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, Others); End User (Hospitals & Clinics, Diagnostic Centers, Others); and Region - Size, Share, Growth Analysis | Forecast (2024 2030)

Global Sepsis Diagnostics by Microbiology Technology Market Size (2024 - 2030)

The estimated value of the Global Sepsis Diagnostics by Microbiology Technology Market was USD 320.81 Million in 2023 and is anticipated to achieve USD 542.73 Million by 2030, demonstrating a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period spanning 2024 to 2030.

Sepsis, or septicemia, is a severe medical condition resulting from the body's reaction to an infection that harms its tissues and organs. It manifests as fever, increased respiratory and heart rates, and mental confusion. Certain infections, like pneumonia, may cause cough, while kidney infections may lead to painful urination. Infants, the elderly, and individuals with weakened immunity may not display typical infection symptoms such as fever, presenting instead with a normal body temperature. Severe cases of sepsis can impair organ function and blood flow, indicated by decreased blood pressure, elevated blood lactate, and low urine output. Septic shock, characterized by persistent low blood pressure despite fluid replacement, can also occur.

Diagnosing sepsis is challenging due to the absence of specific symptoms. Physicians suspect sepsis when there are more than two infections or related indications, conducting a thorough physical examination, various laboratory tests, and closely monitoring the patient's condition. Sepsis can result from various diseases, including pneumonia and diverticulitis, caused by bacteria, viruses, or fungi. The diagnosis involves multiple tests, such as urine and blood tests, along with a comprehensive physical examination to detect infections like abscesses or prostatitis.

Global Sepsis Diagnostics by Microbiology Technology Market Drivers:

The increasing incidence of sepsis propels the growth of the global sepsis diagnostics market using microbiology technology.

Sepsis, a life-threatening condition, can lead to organ damage and septic shock or death if not promptly treated. Approximately 49 million people suffer from sepsis annually, causing 11 million deaths. Preventable community infections and those acquired in healthcare settings drive the demand for sepsis diagnostics by microbiology technology.

The increasing initiatives by national governments and non-governmental entities toward the treatment of sepsis are another factor contributing to the growth of global sepsis diagnostics in the microbiology technology market.

Initiatives by national governments and non-governmental entities to address sepsis also contribute to market growth. Various organizations work to raise awareness through screening, educational campaigns, improved diagnostics, and treatment protocols. Partnerships like the Global Maternal Sepsis Study and Campaign by WHO focus on managing sepsis cases related to maternal health, further boosting the demand for sepsis diagnostics by microbiology technology.

Sepsis Diagnostics by Microbiology Technology Market Challenges:

The global sepsis diagnostics market faces challenges, primarily the high cost of automated diagnostic devices and a shortage of skilled healthcare professionals. While businesses develop advanced diagnostic devices, government hospitals and research labs in emerging nations struggle with budget constraints. Additionally, the shortage of trained paramedics poses a challenge, affecting sepsis awareness, patient identification, and treatment.

Global Sepsis Diagnostics by Microbiology Technology Market Opportunities:

The development of rapid sepsis diagnostic techniques presents a lucrative opportunity. With increasing demand for sepsis diagnostics, companies can capitalize on this by developing rapid diagnostic solutions to minimize delays in antibiotic therapy. This advancement will enhance customer base and overall revenue.

Global Sepsis Diagnostics Market Segmentation Based on Microbiology Technology:

By Product:

• Diagnostic Reagents and Kits
• Blood Culture Media
• Diagnostic Instruments
• Software Solutions

In the year 2022, the segment comprising diagnostic reagents and kits emerged as the leading market segment. The prominence of this segment is attributed to the indispensable role played by diagnostic reagents and kits in sepsis diagnosis. Specific blood biomarkers such as Procalcitonin and C-reactive protein, indicative of sepsis, are efficiently detected using these diagnostic tools. Their simplicity, high sensitivity, and specificity have made them integral to the diagnosis and treatment of sepsis. The rapid identification of sepsis-related biomarkers facilitates prompt initiation of appropriate medical interventions.

By Method:

• Automated Diagnostics
• Conventional Diagnostics

In 2022, the automated diagnostics segment secured the highest market share. This growth is driven by the advantages offered by automated diagnostics, including improved traceability, heightened efficiency, and the elimination of repetitive diagnostic procedures. The escalating demand for timely sepsis treatment has prompted key market players to engage in strategic initiatives such as mergers, acquisitions, partnerships, and portfolio expansions. These strategic moves contribute significantly to the market's overall growth.

By Pathogen Type:

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

The bacterial sepsis segment dominated the market in 2022, primarily due to its higher incidence rate compared to other pathogen types, particularly in healthcare settings. In such environments, individuals are more susceptible to infections, leading to a heightened risk of bacterial sepsis. Swift and timely intervention is crucial for optimal patient care, considering the diverse range of bacteria involved, such as Staphylococcus aureus, Escherichia coli, and Streptococcus pneumoniae.

By End User:

• Hospitals & Clinics
• Diagnostic Centers
• Other Healthcare Facilities

In 2022, the hospitals and clinics segment accounted for the largest market share, driven by the substantial patient influx in these settings. These healthcare facilities provide comprehensive services, equipped with dedicated laboratories and trained medical professionals for effective sepsis diagnostics. The presence of critical care units and emergency departments further facilitates timely intervention and management of septic patients. Hospitalization is often necessary for sepsis cases, and hospitals offer an ideal environment for continuous monitoring and intervention.

By Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

North America emerged as the dominant region in the global sepsis diagnostics market in 2022. The well-established healthcare infrastructure in countries such as the United States and Canada, coupled with a high adoption rate of sepsis diagnostic devices in laboratories and medical clinics, contributed to the region's growth. Favorable healthcare reimbursement policies and the "Get Ahead of Sepsis" campaign by the CDC also played pivotal roles. Key market players in North America include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Luminex Corporation, T2 Biosystems, Inc., and Danaher Corporation.

The Asia-Pacific region is expected to witness the fastest growth over the forecast period. This is attributed to the rising incidence of sepsis, increasing government focus on healthcare infrastructure development in countries such as China, India, and Japan, and growing awareness about sepsis diagnosis and treatment.

Top of Form

COVID-19 Impact on the Global Sepsis Diagnostics by Microbiology Technology Market:

The COVID-19 pandemic significantly impacted the market, disrupting manufacturing, supply chains, and distribution of diagnostic tests and equipment. Lockdowns and social distancing measures caused shortages of skilled workforce and hindered production. The diverted focus on COVID-19 testing further affected the demand for sepsis diagnostics. Despite challenges, the market is expected to recover in the coming years.

Global Sepsis Diagnostics by Microbiology Technology Market Recent Developments:

In August 2022, Becton, Dickinson, and Company (BD) entered a global commercial partnership with Accelerate Diagnostics, Inc., providing rapid testing solutions for detecting antibiotic resistance. In February 2021, Thermo Fisher Scientific Inc. completed the acquisition of Mesa Biotech, Inc.

 Key Players:

1. bioMérieux SA (France)
2. Becton, Dickinson, and Company (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. Bruker Corporation (United States)
5. Luminex Corporation (United States)
6. Cepheid (United States)
7. T2 Biosystems, Inc. (United States)
8. Siemens Healthineers AG (Germany)
9. Danaher Corporation (United States)
10. Immunexpress Inc. (United States)